Can a massive data project finally answer the biggest questions about medical cannabis?

In Part 2 of our conversation with Dr. Johannes Thrul, we explore the National Cannabis Study, an ambitious effort to build a global repository of cannabis research and real-world patient data. From standardized tools like the Cannabis Use Questionnaire to combining datasets from multiple studies, this project aims to uncover how cannabis truly impacts conditions like chronic pain, anxiety, PTSD, and insomnia.

With AI analysis, collaborative research, and a goal of 10,000 participants, the team hopes to transform fragmented cannabis studies into one powerful evidence base.

Listen now to learn how this groundbreaking cannabis database could reshape the future of cannabis medicine.

Johannes Thrul - LinkedIn

Cannabis & Health Research Initiative - website

Transcripts, papers and so much more at: reefermed.ca

What truth can big data unlock about medical cannabis?

Dr. Johannes Thrul from Johns Hopkins talks about cannabis use disorder, psychiatric risks, THC intoxication, and the groundbreaking Cannabis Health Research Initiative.

The ambitious Cannabis Health Research Initiative is a groundbreaking effort to build a national medical cannabis registry and research database. Dr. Thrul shares how the National Cannabis Study will track new medical cannabis users over time, analyze biomarkers and electronic health records, and use AI to identify if medicinal cannabis is helping or not. The goal: generate real-world evidence about the benefits, risks, and clinical applications of cannabinoids—helping researchers design better clinical trials and improve patient care.

Listen now to learn how real-world data may reshape the science of cannabis medicine.

Johannes Thrul - LinkedIn

Cannabis & Health Research Initiative - website

Transcripts, papers and so much more at: reefermed.ca

What will it take for cannabis and natural compounds to truly enter the mainstream—from toothpaste to energy drinks?

In Part 2 of Trevor and Kirk’s conversation with biotech financier and cannabis strategist David Traylor, they discuss how major corporations might explore integrating cannabinoids like CBN and CBD and other natural products into everyday consumer products.

David explains how his Skunk Works Nature AI advisory group connects global companies with world-class experts in pharmacology, biotechnology, and regulatory strategy to develop cannabinoid and other natural product based innovations. From potential sleep-supporting CBN toothpaste, to the role of pharmacogenomics and personalized medicine, this episode explores how science, investment, and product development intersect in the cannabis, psychedelic and natural product sectors.

Trevor and Kirk also unpack the broader forces shaping the cannabis industry—stigma, regulatory barriers, banking challenges, and the tension between single-molecule pharmaceutical approaches vs. whole-plant medicine. Could big brands like PepsiCo or Red Bull be the catalyst that finally normalizes cannabinoid ingredients in consumer products? And what role does fear, policy, and economics play in slowing cannabis acceptance?

Listen now to learn how cannabis science, biotech innovation, and big-industry investment could reshape the future of medicine, consumer products, and natural compounds.

David Traylor - LinkedIn

Skunk Works Nature AI - website

Transcripts, papers and so much more at: reefermed.ca